High-risk human papillomavirus testing versus cytology in predicting post-treatment disease in women treated for high-grade cervical disease: A systematic review and meta-analysis

Gynecologic Oncology

Volumn 125, Issue 2, 2012, Pages 500-507

  Kocken, Mariëlle ^a,b   Uijterwaal, Margot H ^a   De Vries, Anton L M ^a   Berkhof, Johannes ^a   Ket, Johannes C F ^c   Helmerhorst, Theo J M ^b   Meijer, Chris J L M ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c VU UNIVERSITY AMSTERDAM   (Netherlands)

Author keywords

Cervical Intraepithelial Neoplasia (CIN); Conization; Cytology; Diagnostic accuracy; Human papillomavirus (HPV); Recurrence

Indexed keywords

CANCER EPIDEMIOLOGY; CANCER GRADING; CANCER SCREENING; COCHRANE LIBRARY; CONSENSUS; CYTOPATHOLOGY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; EMBASE; EXCISION; FOLLOW UP; GENOTYPE; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; INTERMETHOD COMPARISON; MEDLINE; PRACTICE GUIDELINE; PREDICTIVE VALUE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW; UTERINE CERVIX CARCINOMA IN SITU; VAGINA SMEAR; WART VIRUS;

CERVICAL INTRAEPITHELIAL NEOPLASIA; FEMALE; HUMANS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM, RESIDUAL; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 84859576461     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2012.01.015     Document Type: Review

References (51)

1. Martin-Hirsch PP, Paraskevaidis E, Bryant A, Dickinson HO, Keep SL. Surgery for cervical intraepithelial neoplasia. Cochrane Database Syst Rev 2010;6:CD001318.
2. NvOG. National guideline "cervical intraepithelial neoplasia"; 2004. Accessed on September 28th, 2011.
3. Arbyn M, Sasieni P, Meijer CJ, Clavel C, Koliopoulos G, Dillner J. Chapter 9: clinical applications of HPV testing: a summary of meta-analyses. Vaccine 2006;24(Suppl. 3) S3+78-89.
4. Kreimer AR, Guido RS, Solomon D, Schiffman M, Wacholder S, Jeronimo J, et al. Human papillomavirus testing following loop electrosurgical excision procedure identifies women at risk for posttreatment cervical intraepithelial neoplasia grade 2 or 3 disease. Cancer Epidemiol Biomarkers Prev 2006;15:908-14. (Pubitemid 43823517)
5. Melnikow J, McGahan C, Sawaya GF, Ehlen T, Coldman A. Cervical intraepithelial neoplasia outcomes after treatment: long-termfollow-up from the British Columbia Cohort Study. J Natl Cancer Inst 2009;101:721-8.
6. Prato B, Ghelardi A, Gadducci A, Marchetti I, Di Cristofano C, Di Coscio G, et al. Correlation of recurrence rates and times with posttreatment human papillomavirus status in patients treated with loop electrosurgical excision procedure conization for cervical squamous intraepithelial lesions. Int J Gynecol Cancer 2008;18:90-4.
7. Soutter WP, Sasieni P, Panoskaltsis T. Long-term risk of invasive cervical cancer after treatment of squamous cervical intraepithelial neoplasia. Int J Cancer 2006;118:2048-55.
8. Wright TC. Precancerous lesions of the cervix. In: RJ K, editor. Blaustein's pathology of the female genital tract. 4th ed. New York: Springer Verlag; 1995. p. 248-57.
9. Zielinski GD, Bais AG, Helmerhorst TJ, Verheijen RH, de Schipper FA, Snijders PJ, et al. HPV testing and monitoring of women after treatment of CIN 3: review of the literature and meta-analysis. Obstet Gynecol Surv 2004;59:543-53. (Pubitemid 38802827)
10. Kyrgiou M, Tsoumpou I, Vrekoussis T, Martin-Hirsch P, Arbyn M, Prendiville W, et al. The up-to-date evidence on colposcopy practice and treatment of cervical intraepithelial neoplasia: the Cochrane colposcopy & cervical cytopathology collaborative group (C5 group) approach. Cancer Treat Rev 2006;32:516-23. (Pubitemid 44464136)
11. Paraskevaidis E, ArbynM, Sotiriadis A, Diakomanolis E, Martin-Hirsch P, Koliopoulos G, et al. The role of HPV DNA testing in the follow-up period after treatment for CIN: a systematic review of the literature. Cancer Treat Rev 2004;30:205-11. (Pubitemid 38418058)
12. Colposcopy and programme management. Guidelines for the NHS cervical screening programme. In: Luesley DLS, editor. NHS cancer screening programmes. Second ed. Sheffield: NHS Cancer Screening Programmes; 2010.
13. Bulletins-Gynecology ACoP. ACOG practice bulletin no. 109: cervical cytology screening. Obstet Gynecol 2009;114:1409-20.
14. Alonso I, Torne A, Puig-Tintore LM, Esteve R, Quinto L, Campo E, et al. Pre- and post-conization high-risk HPV testing predicts residual/recurrent disease in patients treated for CIN 2-3. Gynecol Oncol 2006;103:631-6. (Pubitemid 44602179)
15. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12-9. (Pubitemid 29406813)
16. Chan BK, Melnikow J, Slee CA, Arellanes R, Sawaya GF. Posttreatment human papillomavirus testing for recurrent cervical intraepithelial neoplasia: a systematic review. Am J Obstet Gynecol 2009;200(422):e1-9.
17. Nobbenhuis MA, Meijer CJ, van den Brule AJ, Rozendaal L, Voorhorst FJ, Risse EK, et al. Addition of high-risk HPV testing improves the current guidelines on followup after treatment for cervical intraepithelial neoplasia. Br J Cancer 2001;84: 796-801. (Pubitemid 32275653)
18. Strander B, Andersson-Ellstrom A, Milsom I, Sparen P. Long term risk of invasive cancer after treatment for cervical intraepithelial neoplasia grade 3: population based cohort study. BMJ 2007;335:1077.
19. Arbyn M, Paraskevaidis E, Martin-Hirsch P, Prendiville W, Dillner J. Clinical utility of HPV-DNA detection: triage of minor cervical lesions, follow-up of women treated for high-grade CIN: an update of pooled evidence. Gynecol Oncol 2005;99: S7-S11. (Pubitemid 41774340)
20. Cuzick J, Arbyn M, Sankaranarayanan R, Tsu V, Ronco G, Mayrand MH, et al. Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries. Vaccine 2008;26(Suppl. 10): K29-41.
21. Elfgren K, Jacobs M, Walboomers JM, Meijer CJ, Dillner J. Rate of human papillomavirus clearance after treatment of cervical intraepithelial neoplasia. Obstet Gynecol 2002;100:965-71. (Pubitemid 35387469)
22. Kitchener HC, Walker PG, Nelson L, Hadwin R, Patnick J, Anthony GB, et al. HPV testing as an adjunct to cytology in the follow up of women treated for cervical intraepithelial neoplasia. BJOG 2008;115:1001-7. (Pubitemid 351841763)
23. Nobbenhuis MA, Helmerhorst TJ, van den Brule AJ, Rozendaal L, Voorhorst FJ, Bezemer PD, et al. Cytological regression and clearance of high-risk human papillomavirus in women with an abnormal cervical smear. Lancet 2001;358:1782-3. (Pubitemid 33153007)
24. Higgins JPT GS. Cochrane Handbook for Systematic Reviews of Interventions. In: Collaboration TC, editor. Version 5.1.0 ed; 2011.
25. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009;339:b2700.
26. Reitsma JB RA, Whiting P, Vlassov VV, Leeflang MMG, Deeks JJ. Assessing methodological quality. In: Deeks JJ, PM B, C G, editors. Cochrane handbook for systematic reviews of diagnostic test accuracy: the Cochrane Collaboration; 2009.
27. Soderlund-Strand A, Rymark P, Andersson P, Dillner J, Dillner L. Comparison between the Hybrid Capture II test and a PCR-based human papillomavirus detectionmethod for diagnosis and posttreatment follow-up of cervical intraepithelial neoplasia. J Clin Microbiol 2005;43:3260-6. (Pubitemid 40981333)
28. Kang WD, Oh MJ, Kim SM, Nam JH, Park CS, Choi HS. Significance of human papillomavirus genotyping with high-grade cervical intraepithelial neoplasia treated by a loop electrosurgical excision procedure. Am J Obstet Gynecol 2010;203(72): e1-6.
29. Glas AS, Lijmer JG, Prins MH, Bonsel GJ, Bossuyt PM. The diagnostic odds ratio: a single indicator of test performance. J Clin Epidemiol 2003;56:1129-35. (Pubitemid 37386338)
30. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002;21:1539-58. (Pubitemid 34746062)
31. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in metaanalyses. BMJ 2003;327:557-60.
32. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7: 177-88. (Pubitemid 17189972)
33. Freeman MF, Tukey JW. Transformations related to the angular and the square root. Ann Math Stat 1950;21:607-11.
34. Miller JJ. The inverse of the Freeman-Tukey double arscine transformation. Am Stat 1978;32:138.
35. Clopper CJ, Pearson ES. The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika 1934;26:404-13.
36. Agresti A, Min Y. Effects and non-effects of paired identical observations in comparing proportions with binary matched-pairs data. Stat Med 2004;23:65-75. (Pubitemid 38072107)
37. Irwig L, Bossuyt P, Glasziou P, Gatsonis C, Lijmer J. Designing studies to ensure that estimates of test accuracy are transferable. BMJ 2002;324:669-71. (Pubitemid 34234977)
38. Deville WL, Buntinx F, Bouter LM, Montori VM, de Vet HC, van der Windt DA, et al. Conducting systematic reviews of diagnostic studies: didactic guidelines. BMC Med Res Methodol 2002;2:9.
39. Moses LE, Shapiro D, Littenberg B. Combining independent studies of a diagnostic test into a summary ROC curve: data-analytic approaches and some additional considerations. Stat Med 1993;12:1293-316. (Pubitemid 23230833)
40. van Houwelingen HC, Arends LR, Stijnen T. Advanced methods in metaanalysis: multivariate approach and meta-regression. Stat Med 2002;21: 589-624. (Pubitemid 34141379)
41. R Development Core team. R: a language and environment for statistical computing. Vienna, Austria: R foundation for statistical computing; 2010.
42. Zamora J, Abraira V, Muriel A, Khan K, Coomarasamy A. Meta-DiSc: a software for meta-analysis of test accuracy data. BMC Med Res Methodol 2006;6:31.
43. Collaboration TC. Review Manager (RevMan). Copenhagen: the Nordic Cochrane Centre, the Cochrane Collaboration5.1.2 ed.; 2008.
44. Cecchini S, Carozzi F, Confortini M, Zappa M, Ciatto S. Persistent human papilloma virus infection as an indicator of risk of recurrence of high-grade cervical intraepithelial neoplasia treated by the loop electrosurgical excision procedure. Tumori 2004;90:225-8. (Pubitemid 38745612)
45. Heymans J, Benoy IH, Poppe W, Depuydt CE. Type-specific HPV geno-typing improves detection of recurrent high-grade cervical neoplasia after conisation. Int J Cancer 2011;129:903-9.
46. Kocken M, Helmerhorst TJ, Berkhof J, Louwers JA, Nobbenhuis MA, Bais AG, et al. Risk of recurrent high-grade cervical intraepithelial neoplasia after successful treatment: a long-term multi-cohort study. Lancet Oncol 2011;12: 441-50.
47. Sarian LO, Derchain SF, Andrade LA, Tambascia J, Morais SS, Syrjanen KJ. HPV DNA test and Pap smear in detection of residual and recurrent disease following loop electrosurgical excision procedure of high-grade cervical intraepithelial neoplasia. Gynecol Oncol 2004;94:181-6. (Pubitemid 38950517)
48. Smart OC, Sykes P, Macnab H, Jennings L. Testing for high risk human papilloma virus in the initial follow-up of women treated for high-grade squamous intraepithelial lesions. Aust N Z J Obstet Gynaecol 2010;50:164-7.
49. Verguts J, Bronselaer B, Donders G, Arbyn M, Van Eldere J, Drijkoningen M, et al. Prediction of recurrence after treatment for high-grade cervical intraepithelial neoplasia: the role of human papillomavirus testing and age at conisation. BJOG 2006;113:1303-7. (Pubitemid 44581521)
50. Strander B, Ryd W, Wallin KL, Warleby B, Zheng B, Milsom I, et al. Does HPVstatus 6-12 months after treatment of high grade dysplasia in the uterine cervix predict long term recurrence? Eur J Cancer 2007;43:1849-55. (Pubitemid 47238251)
51. De Vet HC, Eisinga A, Riphagen II, Aertgeers B, Pewsner D. Searching for studies. In: Deeks JJ, Bossuyt PM, Gatsonis C, editors. Cochrane handbook for systematic reviews of diagnostic test accuracy: the Cochrane Collaboration; 2008.